Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Clinical Outcomes in Patients With Resectable or Metastatic BRAF+ Melanoma Treated With Dabrafenib and Trametinib in Real Practice

NCT05171374 is registered in ClinicalTrials.gov with MelanomaPRO, Russia as lead sponsor.

NCT NCT05171374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05171374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Clinical Outcomes in Patients With Resectable or Metastatic BRAF+ Melanoma Treated With Dabrafenib and Trametinib in Real Practice
Lead sponsor
MelanomaPRO, Russia
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2021
Completion date
September 30, 2024
Enrollment
500 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma stage iii, melanoma stage iv